How to Choose a Biocompatibility Lab for Upcoming 2026 Global Standards

## How to Choose a Biocompatibility Lab for Upcoming Global Standards Selecting a biocompatibility testing laboratory is a critical decision for any medical device manufacturer. With significant updates to global standards, such as the ISO 10993 series, anticipated in the coming years, this choice has become more complex. Simply verifying a lab’s current accreditations is no longer sufficient for devices with development and submission timelines extending to 2026 and beyond. Manufacturers must adopt a forward-looking evaluation process to ensure their testing partner can navigate evolving regulatory expectations and mitigate future risks. This requires a shift in perspective—from viewing labs as transactional test providers to qualifying them as long-term strategic partners. A future-ready lab does more than execute tests; it provides strategic insight, demonstrates technical agility, and actively prepares for the next generation of standards. Sponsors should proactively assess a laboratory's readiness by examining its involvement in standards development, the flexibility of its Quality Management System, and its depth of expertise in increasingly critical areas like chemical characterization and toxicological risk assessment. ### Key Points * **Accreditation is the Baseline, Not the Finish Line:** While ISO/IEC 17025 accreditation is a mandatory starting point, it only confirms current technical competence. A robust evaluation must look deeper into a lab's proactive processes for adopting future standards. * **Standards Committee Involvement is a Key Indicator:** Laboratories with personnel actively participating in standards development committees (e.g., ISO/TC 194) possess invaluable foresight into draft revisions and the scientific rationale behind upcoming changes. * **Focus on Chemical and Toxicological Depth:** The industry is shifting towards a risk-based approach heavily reliant on chemical characterization (ISO 10993-18) and toxicological risk assessment (ISO 10993-17). A lab’s in-house expertise in these areas is a critical measure of its future-readiness. * **Evaluate the Quality System's Agility:** Inquire about the lab's documented process for validating and implementing new or revised standards. A mature system ensures a smooth transition and minimizes delays for client projects. * **Seek a Strategic Partner, Not Just a Test Executor:** The ideal laboratory partner can help structure a comprehensive Biological Evaluation Plan (BEP) that is scientifically sound and resilient to future regulatory shifts, potentially reducing the need for redundant or unnecessary testing. * **Global Harmonization is Not Guaranteed:** A lab should have demonstrable experience navigating the nuances between major regulatory bodies (e.g., FDA, EU MDR, PMDA), as the adoption and interpretation of revised ISO standards can vary by region. ## Foundational Criteria: Moving Beyond the Basics Before assessing a lab's future-readiness, sponsors must confirm it meets the foundational requirements for quality and competence. ### ISO/IEC 17025 Accreditation: The Starting Point ISO/IEC 17025 is the principal international standard for testing and calibration laboratories. Accreditation to this standard signifies that a laboratory operates a robust quality management system and has demonstrated technical competence to generate valid and reliable results. However, this accreditation is the bare minimum. **Critical Considerations:** * **Scope of Accreditation:** It is crucial to verify that the *specific tests* required for your device are listed within the lab's official scope of accreditation. A lab may be accredited for general biocompatibility testing but not for a highly specialized test, such as a particular chemical analysis method. * **Accrediting Body:** Confirm the accreditation is granted by a recognized body that is a signatory to the International Laboratory Accreditation Cooperation (ILAC) Mutual Recognition Arrangement (MRA). This ensures the acceptance of test results across different countries. ## Evaluating a Laboratory's Future-Readiness: A Due Diligence Framework A forward-looking vendor qualification process goes far beyond a simple certificate check. It involves a deep-dive investigation into a lab's culture, strategy, and technical depth. The following framework outlines key areas to investigate and specific questions to ask potential partners. ### 1. Engagement with Standards Development A laboratory that is passively waiting for new standards to be published is already behind. Proactive labs are actively involved in the conversation, which gives them—and their clients—a significant strategic advantage. **Questions to Ask:** * "Are any of your technical staff, such as study directors or toxicologists, active members of standards development committees like ISO/TC 194 or relevant ASTM groups?" * "How does your organization disseminate information from these committees internally to prepare for upcoming changes?" **Why It Matters:** Participation provides early access to draft standards and, more importantly, a deep understanding of the scientific debate and *intent* behind the changes. This insight allows the lab to advise clients on how to structure testing plans that align with the future direction of regulatory science. ### 2. Quality System and Procedural Agility The transition from an old standard to a revised one can create regulatory uncertainty. A lab with a well-defined and agile Quality Management System (QMS) can manage this transition smoothly and efficiently. **Questions to Ask:** * "Can you provide a high-level overview of your documented process for adopting and validating a revised standard?" * "What is your typical timeline for implementing a newly published ISO standard, from publication to offering the accredited test to clients?" * "How do you manage projects during a transition period when regulators may accept testing to either the old or new version of a standard?" **What to Look For:** A mature lab should be able to describe a clear, multi-step process that includes technical review, method development and validation, staff training, and updating QMS documentation. Their ability to articulate this process demonstrates preparedness and reduces the risk of project delays. ### 3. Technical Expertise in Evolving Areas The future of biocompatibility is increasingly focused on a risk-based approach grounded in analytical chemistry and toxicology, aiming to minimize animal testing. A lab’s investment in these areas is a strong indicator of its long-term viability. #### Chemical Characterization (ISO 10993-18) **Questions to Ask:** * "Describe your team's expertise in analytical chemistry for extractables and leachables (E&L) studies. What analytical techniques (e.g., GC-MS, LC-MS, ICP-MS) do you have in-house?" * "What is your approach to designing an E&L study, including solvent selection and extraction conditions, for a novel polymer-based catheter?" * "How do you establish the Analytical Evaluation Threshold (AET) and manage the identification of unknown compounds?" **Why It Matters:** Poorly designed or executed E&L studies can lead to significant delays and costly regulatory questions. A proficient lab will have experienced chemists who can design scientifically justifiable studies that are compliant with both FDA guidance and ISO standards. #### Toxicological Risk Assessment (ISO 10993-17) **Questions to Ask:** * "What are the qualifications of your toxicology team? Do you have board-certified toxicologists (e.g., DABT) on staff?" * "Can you describe your process for conducting a toxicological risk assessment on chemical characterization data? How do you handle data gaps for compounds with limited toxicological information?" **Why It Matters:** The interpretation of chemical data is as important as the data itself. An in-house team of qualified toxicologists can assess the risk of identified compounds and build a robust justification for device safety, often precluding the need for further biological tests. This capability is essential for any modern biocompatibility program. ## The Vendor Qualification Process in Practice A structured approach to selecting and qualifying a biocompatibility lab ensures a thorough and objective decision. * **Step 1: Request for Information (RFI):** Begin by sending a detailed RFI to a shortlist of potential labs. This document should include the key questions outlined in the framework above, covering standards involvement, QMS agility, and technical depth in chemistry and toxicology. * **Step 2: The Audit (Remote or On-Site):** The audit should be more than a QMS checklist. Request time to interview key technical leaders—the head of analytical chemistry, a senior toxicologist, and experienced study directors. This is an opportunity to gauge their expertise and problem-solving abilities directly. * **Step 3: Evaluate the Proposal:** A strong proposal is not just a price list. It should detail the proposed testing strategy, provide a clear rationale for the selected tests based on your device, and identify potential risks or challenges. It should reflect a deep understanding of your device and its intended use. * **Step 4: Establish a Quality Agreement:** Once a partner is selected, a detailed Quality or Service Level Agreement (SLA) is essential. This document should define communication protocols, turnaround times, the process for handling test failures or deviations, and data reporting formats. ## Strategic Considerations and the Role of Q-Submission For devices involving novel materials, unique manufacturing processes, or a testing plan that deviates from standard practice, early engagement with regulatory bodies is highly recommended. The FDA's Q-Submission program provides a formal mechanism to get feedback on your proposed testing strategy before submission. A strategically-minded biocompatibility lab can be an invaluable partner in this process. They can help prepare the biocompatibility section of the Q-Submission package, including the Biological Evaluation Plan and the rationale for the proposed testing. Presenting a well-reasoned plan, developed with an expert lab, demonstrates proactive diligence to the FDA and can de-risk the subsequent marketing submission, which must be prepared in accordance with regulations such as 21 CFR Part 807. ## Finding and Comparing Biocompatibility Testing Services Providers Choosing the right biocompatibility lab is a long-term strategic decision. It is essential to compare multiple providers not just on price, but on the deeper criteria of future-readiness, technical expertise, and strategic partnership. When evaluating options, create a scorecard based on the frameworks above to objectively assess each lab's capabilities in standards engagement, QMS agility, chemical characterization, and toxicological risk assessment. A small investment in a thorough qualification process can prevent significant regulatory delays and costs in the future. > To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA References When developing a biocompatibility plan for submission to the FDA, sponsors should refer to the latest official documents on the FDA website. Key references include: * FDA's Guidance on the Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process". * FDA's Q-Submission Program guidance for feedback on testing plans. * General regulations for premarket submissions found under Title 21 of the Code of Federal Regulations (21 CFR). This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*